
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health is experiencing strong growth, evidenced by a robust two-year revenue CAGR of 28% expected from 2023 to 2025, driven by anticipated strength in various cancer indications, new monitoring applications, and ongoing product enhancements. The company has demonstrated an optimistic outlook by increasing its annual revenue guidance for the Shield test and projecting a 31% year-over-year growth for 2025. Additionally, Guardant Health's share price has surged, reflecting a substantial market cap approaching $10 billion, which underscores its potential appeal to large fund managers amid increasing demand for its innovative oncology testing solutions.
Bears say
Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, which raises concerns about its growth trajectory. The company's adjusted EBITDA loss of $45.5 million in the third quarter of 2025 underscores ongoing financial challenges that could be exacerbated by potential regulatory setbacks or reimbursement issues. Furthermore, the anticipated reliance on research and development efficiencies, coupled with the need for compelling data, suggests that any negatives in product launches or financial outcomes could significantly impact investor sentiment and stock performance.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares